Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M

Caris Life Sciences, Inc.

2025-Q3 EPS reported -$4.83 revenue$519,147,000

Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).
Gross margin expanded to 68.0% from 43.7% YoY; clinical cases up 18.2% to 50,763.
Positive Adjusted EBITDA of $51.2M and free cash flow of $55.3M.
Full-year 2025 revenue guidance raised to $720-730M, representing 75-77% YoY growth.
Molecular profiling services revenue grew 121.3% YoY to $207.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.